Table 1. Comparison of baseline characteristics and treatment between survivors and non-survivors.
| Variables | Survivors (n = 95) | Non-survivors (n = 123) | P-value |
| Epidemiologics | |||
| Age, yrs | 53.8 ± 11.7 | 55.7 ± 11.2 | 0.216 |
| Male | 70 (73.7%) | 88 (71.5%) | 0.761 |
| Body mass index, kg/m2 | 20.9 ± 3.9 | 20.6 ± 4.1 | 0.640 |
| Co-morbidities | |||
| Coronary atherosclerosis | 7 (7.4%) | 11 (8.9%) | 0.806 |
| Hypertension | 15 (15.8%) | 12 (9.8%) | 0.215 |
| Diabetes mellitus | 43 (45.5%) | 60 (48.8%) | 0.682 |
| Atrial fibrillation | 62 (65.3%) | 91 (74.0%) | 0.181 |
| Previous or current smoking | 60 (63.2%) | 64 (52.0%) | 0.129 |
| Previous or current alcohol use | 38 (40.0%) | 47 (38.2%) | 0.889 |
| Admission vital signs | |||
| SBP, mmHg | 100.4 ± 16.9 | 92.4 ± 11.1 | < 0.001 |
| DBP, mmHg | 63.3 ± 8.8 | 66.4 ± 8.4 | 0.010 |
| Heart rate, bmp | 86.0 ± 18.0 | 90.0 ± 17.0 | 0.087 |
| Lab examination | |||
| BNP, pg/mL | 1206.0 (823.0–2020.0)* | 915.0 (346.0–2416.0)* | 0.352 |
| Troponin I, ug/L | 0.05 (0.04–0.11)* | 0.06 (0.04–1.55)* | 0.084 |
| D-dimer, mg/L | 0.8 (0.5–1.2)* | 1.1 (0.8–2.0)* | < 0.001 |
| Serum creatinine, umol/L | 93.0 (76.6–125.0)* | 105.8 (81.1–162.5)* | 0.023 |
| LVEDD, mm | 73.1 ± 9.5 | 74.4 ± 9.8 | 0.353 |
| LVEF | 35.4% ± 3.9% | 33.6% ± 5.1% | 0.004 |
| Mural thrombus of ventrium | 16 (16.8%) | 23 (18.7%) | 0.859 |
| Drug and device therapy | |||
| Diuretics | 93 (97.9%) | 119 (96.7%) | 0.699 |
| Beta blockers | 37 (38.9%) | 23 (18.7%) | 0.001 |
| ACEIs (or ARBs) | 42 (44.2%) | 44 (35.8%) | 0.212 |
| Aldosterone receptor antagonist | 87 (91.6%) | 101 (82.1%) | 0.049 |
| Digoxin | 66 (69.5%) | 99 (80.5%) | 0.079 |
| Warfarin | 16 (16.8%) | 24 (19.5%) | 0.725 |
| Aspirin | 32 (33.7%) | 66 (53.7%) | 0.004 |
| Clopidogrel | 29 (30.5%) | 59 (48.0%) | 0.012 |
| Amiodarone | 9 (9.5%) | 26 (21.1%) | 0.025 |
| Inotropes/vasoconstrictors | 53 (55.8%) | 69 (56.1%) | 1.000 |
| Ultrafiltration | 20 (21.1%) | 33 (26.8%) | 0.344 |
| VVI or DDD implantation | 10 (10.5%) | 5 (4.1%) | 0.103 |
| CRT (D) implantation | 11 (11.6%) | 11 (8.9%) | 0.651 |
Data are presented as means ± SD or n (%). *Presented as median (25th–75th). ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptors blockers; BNP: brain natriuretic peptide; CRT: cardiac resynchronization therapy; DBP: diastolic blood pressure; LVEDD: left ventricular end diastolic diameter; LVEF: left ventricular ejection fraction; SBP: systolic blood pressure.